Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Inclusion Criteria * Acute HCV infection (or reinfection) within 24 weeks prior to entry * Detectable HCV RNA at the screening visit Exclusion Criteria * Any HCV treatment during the current acute HCV infection episode * Known preexisting cirrhosis * Acute HIV-1 infection * Presence of active or acute AIDS-defining opportunistic infections, active serious infection (other than HIV-1 or HCV), active hepatitis B virus (HBV) or active hepatitis A virus (HAV) * Chronic use of systemically administered immunosuppressive agents * History of solid organ transplantation * History of conditions that could interfere with the absorption of the study drug * Concurrent use of prohibited medications * Known hypersensitivity to glecaprevir or pibrentasvir, the metabolites, or parts of the formulation * Females who are pregnant or breastfeeding * Males with pregnant female partner